Projects per year
Abstract
Non-antigen-specific stimulatory cancer immunotherapies are commonly complicated by off-target effects. Antigen-specific immunotherapy, combining viral tumor antigen or personalized neoepitopes with immune targeting, offers a solution. However, the lack of flexible systems targeting tumor antigens to cross-presenting dendritic cells (DCs) limits clinical development. Although antigen-anti-Clec9A mAb conjugates target cross-presenting DCs, adjuvant must be codelivered for cytotoxic T lymphocyte (CTL) induction. We functionalized tailored nanoemulsions encapsulating tumor antigens to target Clec9A (Clec9A-TNE). Clec9A-TNE encapsulating OVA antigen targeted and activated cross-presenting DCs without additional adjuvant, promoting antigen-specific CD4+ and CD8+ T cell proliferation and CTL and antibody responses. OVA-Clec9A-TNE-induced DC activation required CD4 and CD8 epitopes, CD40, and IFN-α. Clec9A-TNE encapsulating HPV E6/E7 significantly suppressed HPV-associated tumor growth, while E6/E7-CpG did not. Clec9A-TNE loaded with pooled B16-F10 melanoma neoepitopes induced epitope-specific CD4+ and CD8+ T cell responses, permitting selection of immunogenic neoepitopes. Clec9A-TNE encapsulating 6 neoepitopes significantly suppressed B16-F10 melanoma growth in a CD4+ T cell-dependent manner. Thus, cross-presenting DCs targeted with antigen-Clec9A-TNE stimulate therapeutically effective tumor-specific immunity, dependent on T cell help.
Original language | English |
---|---|
Pages (from-to) | 1971-1984 |
Number of pages | 14 |
Journal | The Journal of Clinical Investigation |
Volume | 128 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 May 2018 |
Projects
- 1 Finished
-
Molecular basis for the efficient processing of antigens taken up by Clec9A, a DAMP receptor on dendritic cells
Lahoud, M. (Primary Chief Investigator (PCI)), Caminschi, I. (Chief Investigator (CI)) & Shortman, K. (Chief Investigator (CI))
National Health and Medical Research Council (NHMRC) (Australia)
1/01/15 → 31/12/19
Project: Research